🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "significant breakthrough" in the battle against increasingly resistant strains of the pathogen, according to scientists.

A Global Public Health Issue

The sexually transmitted infection are escalating globally, with data suggesting in excess of 82 million infections annually. Notably increased rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary step in the face of growing infection rates, increasing antimicrobial resistance and the very limited available drugs currently available.”

Health officials are particularly alarmed about the rise in antibiotic-resistant strains. The WHO has classified it as a "priority pathogen". A tracking program revealed that the effectiveness of standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Receive Approval

Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in December for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists hope that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This medication, which is employed against UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to develop it.

“This approval marks a huge turning point in the therapy of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Results and Global Access

Based on results detailed in a major medical journal, the new drug cured the vast majority of cases of the STI. This puts it on an equal footing with the existing first-line therapy, which uses an injection and a pill. The trial involved nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the rights to register and commercialise the drug in numerous low-income and middle-income countries.

Clinicians on the front lines have voiced hope. The availability of a single-dose, oral treatment of this kind is described as a "critical tool" for public health efforts. This is viewed as vital to alleviate the strain of the disease for patients and to stop the proliferation of highly drug-resistant gonorrhoea around the world.